Ventilatory neural drive in chronically hypercapnic patients with COPD: effects of sleep and nocturnal noninvasive ventilation

Alexandra McCartney¹, Devin Phillips¹, Matthew James ¹, Olivia Chan¹, J. Alberto Neder ¹,², Juan P. de-Torres ¹,², Nicolle J. Domnik ³ and Sophie J. Crinion ¹,²

¹Dept of Medicine, Queen’s University, Kingston, ON, Canada. ²Division of Respirology and Sleep Medicine, Kingston Health Sciences Centre, Kingston, ON, Canada. ³Dept of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada.

Corresponding author: Sophie J. Crinion (sophie.crinion@queensu.ca)

Shareable abstract (ERSpublications)
A review outlining our current understanding of the ventilatory neural drive in sleep and chronic hypercapnic respiratory failure in COPD as well as the effect of noninvasive ventilation. Important gaps in the literature are highlighted. https://bit.ly/3AlABJR

Cite this article as: McCartney A, Phillips D, James M, et al. Ventilatory neural drive in chronically hypercapnic patients with COPD: effects of sleep and nocturnal noninvasive ventilation. Eur Respir Rev 2022; 31: 220069 [DOI: 10.1183/16000617.0069-2022].

Abstract
Sleep brings major challenges for the control of ventilation in humans, particularly the regulation of arterial carbon dioxide pressure (\(P_{aCO_2}\)). In patients with COPD, chronic hypercapnia is associated with increased mortality. Therefore, nocturnal high-level noninvasive positive-pressure ventilation (NIV) is recommended with the intention to reduce \(P_{aCO_2}\) down to normocapnia. However, the long-term physiological consequences of \(P_{aCO_2}\) "correction" on the mechanics of breathing, gas exchange efficiency and resulting symptoms (i.e. dyspnoea) remain poorly understood. Investigating the influence of sleep on the neural drive to breathe and its translation to the mechanical act of breathing is of foremost relevance to create a solid rationale for the use of nocturnal NIV. In this review, we critically discuss the mechanisms by which sleep influences ventilatory neural drive and mechanical consequences in healthy subjects and hypercapnic patients with advanced COPD. We then discuss the available literature on the effects of nocturnal NIV on ventilatory neural drive and respiratory mechanics, highlighting open avenues for further investigation.

Introduction
Recent estimates indicate that COPD is the third leading cause of death globally [1]. The disease affects between 300 million and 400 million people worldwide [2, 3] and its prevalence is rising [1, 4]. As COPD progresses in severity, gas exchange and mechanical deficits become more pronounced, decreasing the ability of the respiratory system to remove carbon dioxide (CO\(_2\)). The resultant increase in arterial CO\(_2\) partial pressure (\(P_{aCO_2}\)) eventually becomes persistent, resulting in the development of chronic hypercapnic respiratory failure [5].

The development of chronic hypercapnia in COPD signals advanced disease, carrying an increased risk of death [6]. This has triggered widespread interest in investigating treatment approaches aimed at normalising \(P_{aCO_2}\) in this patient subpopulation. Noninvasive ventilation (NIV) was initially explored as an approach for treating acute hypercapnia in COPD patients in a few centres in the 1960s [7], followed by more widespread use of the treatment of acute respiratory failure in patients with COPD in the 1990s [8]. More recently, the use of nocturnal NIV in COPD patients with chronic hypercapnic respiratory failure has gained renewed momentum owing to the positive documented effects of higher pressure support (difference between inspiratory and expiratory pressures) increasing minute ventilation and reducing \(P_{aCO_2}\) [9–14]. Accordingly, the European Respiratory Society (2019), the American Thoracic Society (2020) and the Canadian Thoracic Society (2021) published clinical practice guidelines recommending the use of nocturnal NIV in stable hypercapnic COPD patients [15–17].
Despite these clinical advances, our knowledge of the complex physiological mechanisms that interact to determine \( P_{\text{ACO}_2} \) in hypercapnic patients with COPD remains limited. This is particularly true during sleep, when the ventilatory neural drive is diminished [18]. Ventilatory neural drive refers to the effenter signalling from the medulla and motor cortex to the respiratory system which controls inspiratory muscle activity and can assist with understanding the physiological mechanisms behind respiratory disease states and symptoms [19]. Abnormalities in gas diffusion and the mechanics of ventilation which characterise COPD may worsen during sleep [20]. Shedding light on the influence of sleep on the ventilatory neural drive and its translation to the mechanical act of breathing is of foremost relevance to create a solid rationale for the use of nocturnal NIV in these patients. After a brief discussion of the mechanisms responsible for ventilatory neural drive in awake and asleep healthy subjects, we outline how sleep may influence ventilatory neural drive in hypercapnic patients with COPD. Based on this conceptual framework, we subsequently review the extant literature on the effects of nocturnal NIV on these outcomes, highlighting the open avenues for further investigation.

**Ventilatory neural drive and mechanical output in healthy subjects: wakefulness and sleep**

**Ventilatory neural drive and mechanical output in awake healthy subjects**

For diaphragm contraction to occur, effenter signals from the innervating phrenic nerve are required; they are the result of central rhythm generation modulated by integrated input from mechanoreceptors within the lungs and airways and chemoreceptors which respond to the partial pressure of dissolved gasses in the blood. In addition, inputs from cortical centres contribute to voluntary respiratory signalling and “wakefulness drive” to breathe [21, 22]. As described earlier, the total effenter signalling from the respiratory centres in the brain to the respiratory muscles is referred to as ventilatory neural drive, and it is often assessed through the surrogate measurement of diaphragmatic activation via diaphragmatic electromyography (EMGdi) [19, 23]. Understanding ventilatory neural drive is useful when studying respiratory diseases, providing information on the efficiency of the ventilatory pump, when used in conjunction with mechanical outputs such as volume and flow.

As the largest and most utilised inspiratory muscle, the diaphragm’s electrical activity is frequently used to indirectly assess neural output, i.e. drive, from the brain’s respiratory centres. EMGdi, measured using an oesophageal catheter placed to assess electrical activity within the crural diaphragm, is currently the predominant metric used to assess diaphragmatic activation [18, 24, 25]. The oesophageal catheter technique has been refined to involve multiple electrode pairs to reduce interfering EMG signals and several studies have verified its validity as a measure of diaphragmatic activation [23, 26, 27]. Measurement of diaphragmatic activation using EMG is especially important in patients with mechanical constraint, given that the inaccuracy of approximating ventilatory neural drive from respiratory output (using variables such as minute ventilation) is exacerbated in these patients, who often exhibit higher levels of disconnect between drive to breathe and ability of the respiratory muscles to respond, known as neuromechanical uncoupling [28, 29].

The respiratory pump includes additional muscles that help to facilitate inspiration, especially during more vigorous ventilation in response to increased mechanical loading. These include the external intercostal muscles, scalene muscles and sternocleidomastoid, which aid in elevating the ribcage during inspiration. In addition, inspiration is aided by muscles supporting the upper airway, including the genioglossus muscle, which moves anteriorly to facilitate airway dilation prior to inspiration [30]. External intercostal innervation originates in the respiratory centres of the medulla; however, external intercostal motor units typically fire with varying frequencies and at different points in time during inspiration when compared to the diaphragm [31]. The scalene muscles are typically active during resting breathing with electrical activity closely mirroring the patterns of the external intercostals during quiet breathing [32]. The sternocleidomastoid typically only becomes activated when lung volume reaches ∼65% of vital capacity [32, 33]. These additional respiratory muscles assume a more prominent role in quiet breathing in advanced respiratory disease [34], and studies have used techniques measuring parasternal surface electromyography (drive to the parasternal intercostal muscles) to assess the efficacy of various treatments used in COPD patient populations [35, 36]. However, recent evidence has demonstrated that this measurement of accessory muscle activity is poorly correlated with lung function in comparison to diaphragm EMG signals, largely due to the limitations in the surface electromyography technique, which introduces “crosstalk” signals from nearby musculature that interfere with measurement of parasternal activity [37].

**Ventilatory neural drive and mechanical output in healthy individuals during sleep**

Sleep introduces significant changes to ventilatory neural drive, respiratory mechanics and gas exchange in healthy individuals. Early studies demonstrated progressive decreases in minute ventilation as a result of
lowered tidal volume ($V_T$) [38] as individuals transition from wakefulness into non-rapid eye movement (NREM) and then into rapid eye movement (REM) sleep [39]. This is in part due to progressive increases in upper airway resistance throughout NREM sleep stages [40, 41] which become even more pronounced during REM sleep. It is thought that a decrease of tonic activity of the genioglossus muscle, which contributes to maintenance of airway patency during NREM sleep, in addition to a large suppression of pharyngeal muscle tone in REM sleep, contribute to airway narrowing and are key contributors to this resistance increase [42]. The gravitational impact of supine positioning may also contribute to the increased resistance through airway narrowing and tongue displacement [43, 44]. This increase in resistance has been shown to cause a minor but detectable increase in CO2 retention in healthy subjects specifically during NREM sleep [45]. In addition, the diaphragm is displaced in the supine position assumed during sleep, and this displacement has been shown to compress the lungs and airways, reducing lung volumes [43, 46]. Hypoxaemia, which sometimes occurs during REM sleep, has been partially attributed to increased $V′/Q′$ mismatching and shunt throughout this phase, as functional residual capacity is lowered as a result of absent tonic diaphragm and intercostal activity [47].

In health, chemosensory responses to both hypercapnia [48] and hypoxia [49] are reduced in NREM and REM sleep [50]. Typically, responses to hypercapnia have been measured through Read’s rebreathing protocol, in which $P_{aCO_2}$ is increased by taking an individual’s expired air and having them re-inspire it [48, 51–53]. Hypercapnic sensitivity can also be assessed through artificial increases in CO2 through a breathing circuit [54]. Although measuring chemosensitivity is a surrogate assessment of ventilatory neural drive to breathe during sleep, a more comprehensive and direct measurement technique is needed to appreciate mechanical, chemical and functional elements contributing to ventilatory drive.

**Ventilatory neural drive in chronically hypercapnic patients with COPD: wakefulness and sleep**

The pathophysiological hallmark of COPD is expiratory flow limitation with consequent air trapping and hyperinflation. The resultant increased mechanical loading of the respiratory system, leading to increased work of breathing, contributes to inability of the respiratory muscles to meet ventilatory drive requirements in many COPD patients. If the ventilatory system response is consistently unable to meet drive requirements, alveolar hypventilation develops and the ability to expel CO2 is compromised, leading to hypercapnia. Severe and persistent hypercapnia, termed hypercapnic respiratory failure, is defined as chronically high $P_{aCO_2}$ (>45 mmHg) [5]. Hypercapnic can also occur acutely, as when acute hypercapnic respiratory failure develops during exacerbations of COPD [55]. Prior acute hypercapnic respiratory failure is a predisposing factor to the development of chronic hypercapnia [56]. A recent multicentre prospective trial from Germany found the prevalence of daytime hypercapnia to be 25% in COPD patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 disease [57]. Daytime hypercapnia is also a predictor of poor prognosis. In a prospective cohort from China, hypercapnic patients had shorter median survival than normocapnic COPD patients [58].

**Chemical, mechanical and direct ventilatory neural mechanisms of chronic hypercapnic respiratory failure**

Ventilatory drive to the diaphragm [59] and other muscles of inspiration (including the scalene and parasternal intercostal muscles) [60] is markedly increased in patients with severe COPD, secondary to complex chemical, mechanical and neural changes. However, the effect of chronic hypercapnia on this elevated ventilatory drive is less well characterised.

**Chemical sources of ventilatory drive in hypercapnic patients**

Central chemoreceptors located in the medulla sense decreased pH within the brain extracellular fluid as well as changes in arterial CO2, altering ventilation to maintain pH within a certain range [61, 62]. In contrast, peripheral chemoreceptors within the carotid body and aorta are predominantly sensitive to hypoxia, a sensitivity that is enhanced during conditions of decreased pH [63]. CO2 behaves as an acid in aqueous solution, such that the central and peripheral chemoreceptors have $P_{aCO_2}$ thresholds of ~45 mmHg and ~39 mmHg, respectively, after which ventilation increases linearly with increasing $P_{aCO_2}$ [64].

In patients with chronic hypercapnia due to severe COPD, chemoreceptor sensitivity may be decreased [65] (figure 1c). Chronically hypercapnic patients with obstructive airway disease have lower ventilatory responses (i.e. sensitivity) to increased $P_{aCO_2}$ (with and without hypoxia) than normocapnic patients with obstructive disease or healthy controls [65, 66]. It is important to consider, when reviewing these findings, that hypercapnic COPD patients are also typically those with the most severe mechanical limitations [67]. Thus, it is difficult to distinguish to what extent blunting of ventilatory responses within such individuals results from mechanical limitations versus decreased chemosensitivity [68]. When BURGRAFF et al. [69]
simulated hypercapnia in goats through 30 days of exposure to high CO₂ levels, they demonstrated no significant alteration in chemoreflex response.

Neuroplasticity of regions of the brain responsible for ventilatory sensing and neural drive may play a role in the altered responses seen in chronic hypercapnic patients, although this hypothesis has thus far only been explored in animal studies. Within the retrotangential nucleus (RTN; a region containing many chemosensory cells relevant to respiration), expression of several neuropeptides decreases with short-term hypercapnia, but increases with chronically elevated \( P_{aCO_2} \) [70]. One of these is galanin, which inhibits ventilatory signals including the acute chemosensory response to hypercapnia and hypoxia when injected into the Bötzinger and pre-Bötzinger complexes of rats [71]. This offers a potential mechanism to explain findings of blunted acute chemosensitivity in hypercapnic patients, although the limitations of applying animal physiology to human physiological function must be considered [70]. However, the neuropeptide neuromedin B, which is an excitatory neurotransmitter potentially implicated in increased minute ventilation, is also expressed in increasing quantities in rat RTN neurons as hypercapnia progresses, which may explain the sustained increase in ventilation during chronic hypercapnia [70].

**Mechanical modulation of ventilatory drive in hypercapnic patients**

COPD results in airways obstruction, ventilation/perfusion (\( V' / Q' \)) mismatch, respiratory muscle dysfunction and hyperinflation, the latter of which leads to diaphragmatic flattening, impaired length–tension relationship of the diaphragm for force generation and consequent changes in breathing pattern (i.e. decreased \( V_T \)) [72–75]. Hyperinflation further contributes to greater intrinsic positive end expiratory pressure that must be overcome to generate inspiration [76]. In concert, the increased work of breathing resulting from these mechanical deficits requires increased ventilatory neural drive from the respiratory centres within the brain to maintain or attempt to maintain appropriate ventilation per metabolic load in face of reduced ventilatory capacity (figures 1a and 2) [77, 78]. Interestingly, hypercapnia itself may contribute to the perpetuation of this cycle, as even 21 days of chronic hypercapnia increases airway smooth muscle contractility and constriction in response to acetylcholine through a caspase-7-mediated...
mechanism in murine models [78]. This hypercapnia-mediated increase in contractility may potentiate airways resistance and load in hypercapnic COPD patients, which in turn could further increase ventilatory drive through mechanosensory afferent pathways [79]. In addition, cellular and molecular changes within the diaphragm contribute to mechanical limitations in chronic hypercapnic respiratory failure. On the level of individual cells, diaphragmatic muscle fibres from patients with severe COPD generate less force than those within the diaphragms of healthy controls (figure 1a) [80]. However, the proportion of slow-twitch fibres within the diaphragm is increased in COPD patients, indicating a potential increase in fatigue resistance to compensate for higher ventilatory load [81]. It is still unclear whether this compensation is able to prevent or delay the onset of hypercapnic respiratory failure; more investigation is needed in this domain.

An additional and significant factor contributing to gas exchange derangement and eventual hypercapnia, which is linked to both mechanical and chemical alterations, is $V′/Q′$ mismatch (see figure 1b). In early COPD, $V′/Q′$ inequality presents, in part, through early collapse of small airways and impaired alveolar ventilation prior to larger airways becoming impacted and altering spirometry [73]. Concurrent destruction of pulmonary capillaries increases the proportion of ventilation that enters poorly perfused alveoli (creation of physiological dead space), further contributing to $V′/Q′$ mismatch. There is also more recent evidence to suggest that some COPD patients may present with a “vascular phenotype” of disease which leads to early $V′/Q′$ inequality, in which vascular pruning and vascular dysfunction, as opposed to emphysematous destruction of capillary beds, is the predominant contributor to $V′/Q′$ mismatch as a result of poor perfusion [82]. Finally, the creation of dead space as a result of airway collapse and perfusion limitation...
leads to a higher required level of minute ventilation in order to facilitate sufficient gas exchange. Patients with severe COPD and mechanical limitation are often unable to meet this requirement and CO₂ retention is the result.

**Direct neural inputs to the diaphragm**

Direct neural inputs to the diaphragm via the corticospinal pathway allow for voluntary control of the diaphragm and facilitate nonventilatory activities such as speech [83]. These pathways have been assessed by way of transcranial magnetic stimulation and measurement of resultant motor evoked potentials of the diaphragm [84]. Signalling to the diaphragm initiated in the cortex through the corticospinal pathway contributes to neural drive in the waking state and is essential for resisting apnoeas induced by hypocapnia [85]. This drive is predominantly provided by excitatory stimulation of the cortex via the reticular activating system during wakefulness, allowing for continuation of breathing even without medullary centre input [86].

Evidence suggests that the corticospinal tract is almost maximally activated in awake COPD patients [87] and there is a ceiling effect of the corticospinal signal in COPD patients not seen in healthy controls [88]. However, in COPD patients with elevated $P_{aCO₂}$, findings are inconsistent, with some studies suggesting that corticospinal inhibition of the diaphragmatic motor cortex is increased in hypercapnia [87], while others demonstrating increased voluntary activation of the diaphragm possibly conferring protective advantages in face of worsened mechanics [89]. Such findings have been obtained in relatively small sample sizes, and further work is needed to definitively identify the impact of chronic hypercapnia on ventilatory neural drive. Relative changes in input from medullary respiratory centres may also contribute to changes in drive, but their respective contributions in severe COPD and/or hypercapnia have not been characterised.

**Ventilatory neural drive in sleeping patients with hypercapnic COPD**

Despite persistently elevated daytime ventilatory neural drive in patients with COPD, neural drive changes occurring during sleep may especially predispose patients with impaired respiratory mechanics to nocturnal hypoventilation. To date, EMG$_{di}$ has been acquired in few overnight studies in patients with COPD. **LUO et al.** [18] demonstrated greater declines in EMG$_{di}$ during the transition from wakefulness to NREM and REM sleep in normocapnic COPD versus healthy controls despite consistently higher overall drive in COPD patients, concluding that such decreases in drive may contribute to hypventilation in hypercapnia during sleep (figure 3a). This is supported by recent findings showing greater loss of EMG$_{di}$ in the transition from wakefulness to sleep in normocapnic COPD than in health [90]. Such nocturnal hypercapnia is predicted to precede the onset of persistent daytime hypercapnia [91]. As described in the preceding section, corticospinal input to the respiratory centres contributes to neural drive in the waking state, but much of this input is lost during sleep. This has potential to contribute to the drop in EMG$_{di}$ observed in the transition to sleep. It may also be postulated that the loss of this wakefulness drive could have exaggerated impacts on COPD patients as compared to the healthy population, due to impaired ability to compensate for the increasing mechanical and chemical deficits which we have described in hypercapnic COPD, thus increasing vulnerability to hypoventilation. Interestingly, decreases in EMG$_{di}$ in the transition to sleep may occur in the presence of preserved ventilatory effort (oesophageal and transdiaphragmatic pressure) in normocapnic COPD [90].

In addition to disturbed mechanical inputs to the respiratory centres, disrupted chemical afferent inputs to the central rhythm generator in the medulla in COPD patients during sleep may facilitate hypoventilation and promote CO₂ retention (figure 3d). The decreased sensitivity of chemoreceptors to both hypercapnia and hypoxia throughout sleep [92] which causes minimal disturbance in healthy subjects can be deleterious when compounded by the mechanical limitations and blunted chemosensory responses in COPD patients [93]. Furthermore, diaphragmatic flattening due to hyperinflation may cause COPD patients to increase use of accessory inspiratory muscles to maintain ventilation during the daytime and portions of the night [94]. However, REM sleep-associated muscle atonia disproportionately affects inspiratory muscles other than the diaphragm [95, 96], leading to a presumed reliance on the diaphragm to maintain adequate ventilation [97] during REM sleep (figure 3c). This may leave COPD patients who rely in larger part on nondiaphragmatic inspiratory muscles without adequate means to generate pressure during REM sleep, contributing to sleep hypoventilation. Insufficient pressure generation from the diaphragm also encourages patients to adopt a rapid shallow breathing pattern [98], which leads to a higher percentage of ventilation within anatomical dead space, and less efficient gas exchange [99]. Accordingly, hypopnea and associated hypercapnia typically first present during REM sleep [20]. However, emerging evidence suggests that REM sleep atonia of inspiratory muscles apart from the diaphragm may not be as universal as previously believed. In patients with severe COPD recovering from exacerbation, evidence of additional...
inspiratory muscle activity has been documented during REM sleep [100]. Similarly, maintained activity of other inspiratory muscles, including the parasternal intercostals, has been demonstrated in healthy individuals during REM sleep [101], suggesting that inhibition of inspiratory muscles may be a less significant factor in sleep hypoventilation than once believed.

The prevalence of sleep disordered breathing, in particular, obstructive sleep apnoea (OSA), is high in patients with severe lung disease [102], which can further exacerbate declines in lung function and derangement of blood gases overnight. High apnoea–hypopnea index scores, which indicate the existence of OSA, have been found to be inversely correlated with forced expiratory volume in 1 s (FEV1)/forced vital capacity, indicating that this condition disproportionately affects severe COPD patients [103]. Increased airway inflammation and larger and more frequent oxygen desaturations may contribute to hypoventilation and eventual hypercapnia in OSA patients. Additionally, COPD patients frequently experience arousal from sleep, which can be made even worse by coexistent OSA [104]. These arousals have been associated with increased neural drive, which could complicate our understanding of ventilatory drive during sleep and changes in blood gases [26, 70]. However, the details of COPD–OSA overlap and arousals are beyond the scope of this article, as we aim to predominantly review the physiological underpinnings of hypercapnic COPD in isolation.

Treatments targeted towards improving ventilation during sleep include nocturnal bronchodilator therapy and oxygen supplementation. While dual long-acting nocturnal bronchodilators decrease airways resistance and sleeping ventilatory effort and ventilatory neural drive in moderate COPD [105, 106], nocturnal long-term oxygen therapy improves oxygenation in patients with persistent hypoxaemia [107] decreasing minute ventilation through reduction of a chemosensory stimulus [108]. These approaches are often insufficient when treating severe COPD with hypercapnia [109]. Recently, nocturnal NIV has gathered significant interest as an effective means of improving blood gas levels in hypercapnic COPD patients and contributing to improved symptom profile [110].

![Impact of sleep on breathing in health...](https://doi.org/10.1183/16000617.0069-2022)

| Impact of sleep on breathing in health... |
|-----------------------------------------|
| a) ↓ Wakefulness cortical inputs         |
| b) ↓ Accessory inspiratory muscle activity (REM) |
| c) ↓ Upper airway resistance            |
| d) ↓ Chemosensitivity (hypercapnia, hypoxia) |

... and additionally in COPD

| ↓ Sleep-related neural drive             |
| ↑ V'/Q' mismatch                        |
| Diaphragmatic mechanical disadvantage   |
| ↓ Chemosensory response                 |

FIGURE 3 Physiological changes during sleep in normal subjects and COPD. a) During sleep, a decrease in ventilatory neural drive is observed. Despite higher baseline drive in COPD patients, a larger drop from wakefulness to sleep is typically noted in this population. b) Increased airway resistance during sleep may exacerbate the ventilation/perfusion (V'/Q') mismatching experienced in COPD. c) Accessory inspiratory muscle activity is typically eliminated during rapid eye movement (REM) sleep, necessitating a reliance on the diaphragm. However, in COPD patients with compromised diaphragm activity, hypoventilation may result from this loss of accessory muscle activity. d) Finally, decreased chemosensitivity in sleep compounds the existing reduction in chemosensitivity experienced by COPD patients, especially those with elevated arterial partial pressure of carbon dioxide. These changes in sleep compounded on the limitations on COPD patients can contribute to sleep hypoventilation in this population.
Nocturnal NIV in COPD

Nocturnal NIV directly addresses some of the overnight mechanical and neural challenges which contribute to chronic hypercapnic respiratory failure in COPD patients, showing outcome benefits over other therapies including nasal high-flow therapy [111] or long-term oxygen therapy alone [112]. NIV became utilised for acute respiratory failure in patients with COPD shortly after its initial use on patients with neuromuscular disease and paralysis [113]. Investigation into the use of high-intensity NIV (a form of NIV that uses high inspiratory pressures to help normalise $P_{aCO2}$, to treat stable chronic hypercapnic COPD) began in the early 2010s, with early studies delivering promising results: improved health-related quality of life, reduced sleep hypventilation and improved daytime lung function [9, 10].

When is NIV indicated in COPD?

The European Respiratory Society, American Thoracic Society and Canadian Thoracic Society acknowledge the benefits of NIV in stable hypercapnic COPD, with the most recent clinical practice guidelines of each recommending the initiation of NIV once a stable patient reaches a specific $P_{aCO2}$ threshold [15–17]. While there is some variance in the precise threshold employed by each society, this probably reflects the diversity of mean $P_{aCO2}$ of patients using NIV across studies [16].

Mechanisms of NIV in hypercapnic COPD

Despite the large body of literature documenting clinical outcomes of NIV, many questions remain on the physiological mechanisms contributing to its efficacy. Here, we will introduce several proposed mechanisms of action of NIV while highlighting gaps in the literature warranting further exploration.

Unloading the diaphragm

NIV is proposed to improve outcomes in chronic hypercapnic respiratory failure, in part through reduction of diaphragm workload (figure 4b). DUIVERMAN et al.’s [12] study, which looked at costal diaphragm activity via surface EMG in awake COPD patients with hypercapnia, found significant reductions in EMG activity during NIV versus unassisted breathing, with even more pronounced reductions when a high inspiratory pressure was used. A modified mode of noninvasive ventilation, proportional assist ventilation, which uses the patient’s breathing effort as measured by a pneumotachograph to determine assistive pressure and flow [114] also reduces costal diaphragm EMG via surface electrode by ~38% when accounting for changes in minute ventilation [115]. It should be noted that diaphragm activity has only been measured through surface electrodes during NIV. This comes with technical limitations, as surface signals from the costal diaphragm are often skewed by artefact from nearby muscles of the chest wall [116]. The oesophageal catheter technique of measuring crural diaphragm EMG activity can eliminate some of this extraneous muscle crosstalk, improving specificity of measurement. Moreover, the activity of the diaphragm (costal or crural) during NIV in sleep has not been directly reported in the literature and must be explored to confirm that diaphragm unloading contributes to the efficacy of NIV in improving ventilation overnight.

Reduction of hyperinflation

Hyperinflation, which is a hallmark of COPD, can worsen overnight (figure 4a) [90, 105]. Combined with the deleterious impact of sleep on airway resistance, inspiratory muscle activity and breathing pattern, this hyperinflation can also lead to exaggerated hypoventilation and hypercapnia overnight [117]. Dynamic hyperinflation, characterised by positive end-expiratory pressure changes, is significantly reduced in COPD patients randomised to daytime NIV for 3 h, 5 days per week over 3 weeks, and this reduction is associated with decreased hypercapnia (~1.12 mmHg) [118]. It was postulated that the reduced hyperinflation may have been the result of a longer time available for expiration due to reduced respiratory rate facilitated by NIV, which resulted in more effective emptying and a reduction in gas trapping [118]. NIV used overnight may also significantly improve daytime hyperinflation, as described in a group of severe COPD patients (GOLD stage IV) undergoing simultaneous pulmonary rehabilitation [13]. Residual volume/total lung capacity (used to assess lung hyperinflation) significantly improved in patients using NIV and pulmonary rehabilitation and remained unchanged in patients completing pulmonary rehabilitation alone [13]. Improvements in hyperinflation may in turn improve lung function, with some literature pointing to a reduced decline, or even slight increase in FEV1 in patients using NIV as compared to other forms of treatment alone [119].

Improvement in V/Q mismatching

As described in the section on ventilatory neural drive in awake hypercapnic patients with COPD, $V/Q$ mismatch due to small airway and alveolar collapse is common in COPD. Although some of the poorly ventilated pulmonary perfusion that results can be rerouted to more ventilated regions through pulmonary hypoxic vasoconstriction [120], areas of physiological shunt remain, which can result in the development
of hypoxia. The ability of NIV to provide positive end-expiratory pressure functions to maintain airway patency and improve expiratory flow [121]. This pressure has been shown to recruit previously collapsed alveoli when used in patients with hypoxaemic acute respiratory failure [122]. This could potentially allow for ventilation in previously shunted regions, improving $V'/Q'$ matching, resulting in oxygenation along with CO₂ removal (figure 4c).

**NIV resetting central drive**

It has been theorised that the improvements seen in NIV during sleep may also be the result of a “reset” in respiratory drive initiated by normalisation of $P_{aCO_2}$, which persists during the daytime to improve daytime $P_{aCO_2}$ in addition to acutely improving nocturnal $P_{aCO_2}$ during sleep (figure 4d). This is supported by two small studies [123, 124] which used rebreathing protocols to measure chemosensitivity to CO₂ during the daytime, and found improvements in sensitivity after nocturnal NIV treatment and resultant decreases in daytime $P_{aCO_2}$.

To date, few investigators have attempted to acutely characterise the impact of NIV on ventilatory neural drive to breathe. One study acutely assessed neural drive via parasternal electromyography during overnight NIV in a cohort of hypercapnic COPD patients to detect patient ventilator asynchrony; however, the impact of NIV on magnitude of and possible alterations in neural drive were not thoroughly characterised through the use of EMGdi to measure diaphragm activation [36].

**Conclusion**

The deleterious effects of advanced COPD on lung and airway mechanics, gas exchange and respiratory muscle function [125] impair the ability of the ventilatory system to effectively clear CO₂, ultimately resulting in chronic hypercapnic respiratory failure [5]. Nocturnal NIV has been successfully integrated
into clinical practice guidelines, and studies have shown promising data on its ability to improve clinical outcomes. However, much of the research on physiological mechanisms behind the efficacy of NIV relies on surrogate rather than direct measurement of ventilatory neural drive or has investigated the use of NIV during wakefulness. These shortcomings are acknowledged by recent clinical practice guidelines, which recommend further research in the area of physiological underpinnings of NIV. Such an understanding is prerequisite to developing setting recommendations for individual patients and may be facilitated by measurement of ventilatory neural drive and consequent mechanical responses to nocturnal NIV. Advances in techniques for measuring these physiological indices are increasingly available, and reports on this exciting yet complex process are eagerly anticipated.

**Future research questions**

- What is the impact of NIV on ventilatory neural drive (as measured by diaphragm EMG) overnight?
- What is the impact of long-term use of NIV on daytime ventilatory neural drive (as measured by EMG<sub>di</sub>)?
- How do cellular changes within the diaphragm in COPD impact the progression of chronic hypercapnic respiratory failure?
- What is the precise P<sub>aCO</sub><sub>2</sub> threshold at which NIV is beneficial for patient clinical outcomes?
- What are the relative contributions of ventilatory versus perfusion limitations to the development of chronic hypercapnic respiratory failure?
- Does the impact of long-term NIV on ventilatory neural drive affect daytime perceptions of dyspnoea and associated exercise intolerance?

Provenance: Submitted article, peer reviewed.

Conflict of interest: A. McCartney reports no conflicts of interest. D. Phillips reports no conflicts of interest. M. James reports no conflicts of interest. O. Chan reports no conflicts of interest. J.A. Neder reports no conflicts of interest. J.P. de-Torres reports no conflicts of interest. N.J. Domnik reports no conflicts of interest. S.J. Crinion reports no conflicts of interest.

Support statement: This article was supported by William M. Spear Endowment in Pulmonary Research/Richard K. Start Memorial Fund (respiratory diseases) awarded to S.J. Crinion (PI) and N.J. Domnik (co-investigator) in 2021. Funding information for this article has been deposited with the Crossref Funder Registry.

**References**

1. World Health Organization (WHO). The Top 10 Causes of Death. 2020. www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death Date last updated: 9 December 2020.

2. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015; 5: 020415.

3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–2196.

4. Beran D, Zar HJ, Perrin C, et al. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med 2015; 3: 159–170.

5. Budweiser S, Jüres RA, Pleifer M. Treatment of respiratory failure in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 605–618.

6. Ambrosino N, Simonds A. The clinical management in extremely severe COPD. Respir Med 2007; 101: 1613–1624.

7. Sadoul P, Aug MC, Gay R. Traite par ventilation instrumentale de 100 cas d’insuffisance respiratoire aiguë sévère (PB<sub>aCO</sub><sub>2</sub> égale ou supérieure à 70 mmHg) chez les pulmonaires chroniques. [Treatment by mechanical ventilation of 100 cases of severe acute respiratory failure (P<sub>aCO</sub><sub>2</sub> equal to or greater than 70 mmHg) in chronic lung patients]. Bull Physiopathol Respir 1965; I: 335–344.

8. Brochard L, Isabeau D, Piquet J, et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990; 323: 1523–1530.

9. Dreher M, Storre JH, Schmoor C, et al. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax 2010; 65: 303–308.

10. Weir M, Marchetti N, Czysz A, et al. High intensity non-invasive positive pressure ventilation (HINPPV) for stable hypercapnic chronic obstructive pulmonary disease (COPD) patients. Chronic Obstr Pulm Dis 2015; 2: 313–320.

11. Murphy PB, Brignall K, Moxham J, et al. High pressure versus high intensity noninvasive ventilation in stable hypercapnic chronic obstructive pulmonary disease: a randomized crossover trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 811–818.
Jolley CJ, Luo YM, Steier J, Sarkar M, Bhardwaj R, Madabhavi I, Domnik NJ, Walsted ES, Langer D. Clinical utility of measuring inspiratory neural drive during

Douglas NJ, White DP, Pickett CK, et al. Respiration during sleep in normal man. Thorax 1982; 37: 840–844.
Lorino AM, Atlan G, Lorino H, Katz S, Arish N, Rokach A, Kay A, Trinder J, Kim Y. Progressive changes in airway resistance during sleep. J Appl Physiol 1996; 81: 282–292.

Hudgel DW, Martin RJ, Johnson B, et al. Mechanics of the respiratory system and breathing pattern during sleep in normal humans. J Appl Physiol Respir Environ Exerc Physiol 1984; 56: 133–137.

Horner RL. Control of genioglossus muscle by sleep state-dependent neuromodulators. Adv Exp Med Biol 2008; 605: 262–267.

Katz S, Arish N, Rokach A, et al. The effect of body position on pulmonary function: a systematic review. BMC Pulm Med 2018; 18: 159.

Lorino AM, Atlan G, Lorino H, et al. Influence of posture on mechanical parameters derived from respiratory impedance. Eur Respir J 1992; 5: 1118–1122.

Skatrud JB, Dempsey JA, Badr S, et al. Effect of airway impedance on CO2 retention and respiratory muscle activity during NREM sleep. J Appl Physiol 1988; 65: 1676–1685.

Wade OL, Gilson JC. The effect of posture on diaphragmatic movement and vital capacity in normal subjects with a note on spirometry as an aid in determining radiological chest volumes. Thorax 1951; 6: 103–126.

Fletcher EC, Gray BA, Levin DC. Nonapneic mechanisms of arterial oxygen desaturation during rapid-eye-movement sleep. J Appl Physiol Respir Environ Exerc Physiol 1983; 54: 632–639.

Douglas NJ, White DP, Weil JV, et al. Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis 1982; 126: 758–762.

Berthon-Jones M, Sullivan CE. Ventilatory and arousal responses to hypoxia in sleeping humans. Am Rev Respir Dis 1982; 125: 632–639.

Corfield DR, Roberts CA, Griffiths MJ, et al. Sleep-related changes in the human ‘neuromuscular’ ventilatory response to hypoxia. Respir Physiol 1999; 117: 109–120.

Issa FG, Bitner S. Effect of route of breathing on the ventilatory and arousal responses to hypercapnia in awake and sleeping dogs. J Physiol 1993; 465: 615–628.

Phillipson EA, Kozar LF, Rebuck AS, et al. Ventilatory and waking responses to CO2 in sleeping dogs. Am Rev Respir Dis 1977; 115: 251–259.

Berthon-Jones M, Sullivan CE. Ventilation and arousal responses to hypercapnia in normal sleeping humans. J Appl Physiol Respir Environ Exerc Physiol 1984; 57: 59–67.

Cummin AR, Sidhu VS, Telford RJ, et al. Ventilatory responsiveness to carbon dioxide below the normal control point in conscious normoxic humans. Eur Respir J 1992; 5: 512–516.

Csoma B, Vulpi MR, Dragonieri S, et al. Hypercapnia in COPD: causes, consequences, and therapy. J Clin Med 2022; 11: 3180.

Dave C, Wharton S, Mukherjee R, et al. Development and relevance of hypercapnia in COPD. Can Respir J 2021; 2021: 6623093.

Dreher M, Neuzeret PC, Windisch W, et al. Prevalence of chronic hypercapnia in severe chronic obstructive pulmonary disease: data from the HOMEVent Registry. Int J Chron Obstruct Pulmon Dis 2019; 14: 2377–2384.

Yang H, Xiang P, Zhang E, et al. Is hypercapnia associated with poor prognosis in chronic obstructive pulmonary disease? A long-term follow-up cohort study. BMJ Open 2015; 5: e008909.

De Troyer A, Leeper JB, McKenzie DK, et al. Neural drive to the diaphragm in patients with severe COPD. Am J Respir Crit Care Med 1997; 155: 1335–1340.

Gandevia SC, Leeper JB, McKenzie DK, et al. Discharge frequencies of parasternal intercostal and scalene motor units during breathing in normal and COPD subjects. Am J Respir Crit Care Med 1996; 153: 622–628.

Guyenet PG, Stornetta RL, Bayliss DA. Central respiratory chemoreception. J Comp Neurol 2010; 518: 3883–3906.

Kellum JA. Determinants of blood pH in health and disease. Crit Care 2000; 4: 6–14.

Kumar P, Prabhakar NR. Peripheral chemoreceptors: function and plasticity of the carotid body. Compr Physiol 2012; 2: 141–219.

Duffin J, McAvoj GV. The peripheral-chemoreceptor threshold to carbon dioxide in man. J Physiol 1988; 406: 15–26.

Kepron W, Cherniack RM. The ventilatory response to hypercapnia and to hypoxemia in chronic obstructive lung disease. Am Rev Respir Dis 1973; 108: 843–850.

Lourenço RV, Miranda JM. Drive and performance of the ventilatory apparatus in chronic obstructive lung disease. N Engl J Med 1968; 279: 53–59.

Calverley PM. Respiratory failure in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: Suppl. 47, 26s–30s.

Loring SH, Garcia-Jacques M, Malhotra A. Pulmonary characteristics in COPD and mechanisms of increased work of breathing. J Appl Physiol 2009; 107: 309–314.

Burgraff NJ, Neumuller SE, Buchholz K, et al. Ventilatory and integrated physiological responses to chronic hypercapnia in goats. J Physiol 2018; 596: 5343–5363.
Reed DJ, Kellogg RH. Changes in respiratory response to CO2 during natural sleep at sea level and at Holmedahl NH, Øverland B, Fondenes O, Domnik NJ, Phillips DB, James MD, Topeli A, Laghi F, Tobin MJ. The voluntary drive to breathe is not decreased in hypercapnic patients with Hopkinson NS, Sharshar T, Ross ET, Dubois M, Chenivesse C, Raux M, Martin TJ, Sanders MH. Chronic alveolar hypoventilation: a review for the clinician. Hutt DA, Parisi RA, Edelman NH, Dal Vecchio L, Polese G, Poggi R, et al. “Intrinsic” positive end-expiratory pressure in stable patients with chronic obstructive pulmonary disease. Decramer M. Hyperinflation and respiratory muscle interaction. Dal Vecchio L, Polese G, Poggi R, et al. Intrinsic” positive end-expiratory pressure in stable patients with chronic obstructive pulmonary disease. Eur Respir J 1990; 3: 74–80. Martin TJ, Sanders MH. Chronic alveolar hypoventilation: a review for the clinician. Sleep 1995; 18: 617–634. Shigemura M, Lecuona E, Angulo M, et al. Hypercapnia increases airway smooth muscle contractility via caspase-7-mediated miR-133a-RhoA signaling. Sci Transl Med 2018; 10: eaat1662. Hutt DA, Parisi RA, Edelman NH, Dal Vecchio L, Polese G, Poggi R, et al. Intrinsic” positive end-expiratory pressure in stable patients with chronic obstructive pulmonary disease. Eur Respir J 1990; 3: 74–80. Martin TJ, Sanders MH. Chronic alveolar hypoventilation: a review for the clinician. Sleep 1995; 18: 617–634. Shigemura M, Lecuona E, Angulo M, et al. Hypercapnia increases airway smooth muscle contractility via caspase-7-mediated miR-133a-RhoA signaling. Sci Transl Med 2018; 10: eaat1662.
100 Redolfi S, Grassion L, Rivals I, et al. Abnormal activity of neck inspiratory muscles during sleep as a prognostic indicator in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 201: 414–422.

101 Yokoba M, Hawes HG, Kieser TM, et al. Parasternal intercostal and diaphragm function during sleep. J Appl Physiol 2016; 121: 59–65.

102 Akinci B, Aslan GK, Kiyani E. Sleep quality and quality of life in patients with moderate to very severe chronic obstructive pulmonary disease. Clin Respir J 2018; 12: 1739–1746.

103 Zhang XL, Dai HP, Zhang H, et al. Obstructive sleep apnea in patients with fibrotic interstitial lung disease and COPD. J Clin Sleep Med 2019; 15: 1807–1815.

104 Fleetham J, West P, Mezon B, et al. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis 1982; 126: 429–433.

105 Dominik NJ, James MD, Scheeren RE, et al. Deterioration of nighttime respiratory mechanics in COPD: impact of bronchodilator therapy. Chest 2021; 159: 116–127.

106 Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013; 14: 49.

107 Lacasse Y, Sériès F, Corbeil F, et al. Randomized trial of nocturnal oxygen in chronic obstructive pulmonary disease. N Engl J Med 2020; 383: 1129–1138.

108 Peters MM, Webb KA, O’Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax 2006; 61: 559–567.

109 Meecham Jones DJ, Paul EA, Jones PW, et al. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152: 534–544.

110 Duiverman ML. Noninvasive ventilation in stable hypercapnic COPD: what is the evidence? ERJ Open Res 2018; 4: 00012-2018.

111 McKinstry S, Singer J, Baarsma JP, et al. Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure: a randomized controlled cross-over trial. Respirology 2019; 24: 1081–1087.

112 Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 2017; 317: 2177–2186.

113 Meduri GU, Conoscenti CC, Menashe P, et al. Noninvasive face mask ventilation in patients with acute respiratory failure. Chest 1989; 95: 865–870.

114 Gay PC, Hess DR, Hill NS. Noninvasive proportional assist ventilation for acute respiratory insufficiency. Comparison with pressure support ventilation. Am J Respir Crit Care Med 2001; 164: 1606–1611.

115 Polese G, Vitacca M, Bianchi L, et al. Nasal proportional assist ventilation unloads the inspiratory muscles of stable patients with hypercapnia due to COPD. Eur Respir J 2000; 16: 491–498.

116 Sinderby C, Friberg S, Comtois N, et al. Chest wall muscle cross talk in canine costal diaphragm electromyogram. J Appl Physiol 1996; 81: 2312–2327.

117 O’Donoghue FJ, Catcheside PG, Ellis EE, et al. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors. Eur Respir J 2003; 21: 977–984.

118 Díaz Q, Bégin P, Torrealba B, et al. Effects of noninvasive ventilation on lung hyperinflation in stable hypercapnic COPD. Eur Respir J 2002; 20: 1490–1498.

119 Duiverman ML, Wempe JB, Bladder G, et al. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Respir Res 2011; 12: 112.

120 Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest 2017; 151: 181–192.

121 MacIntyre NR. Physiologic effects of noninvasive ventilation. Respir Care 2019; 64: 617–628.

122 Artaud-Macari E, Bubenheim M, Le Boura G, et al. High-flow oxygen therapy versus noninvasive ventilation: a randomised physiological crossover study of alveolar recruitment in acute respiratory failure. ERJ Open Res 2021; 7: 00373-2021.

123 Elliott MW, Mulvey DA, Moxham J, et al. Domiciliary nocturnal nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial blood gas tensions. Eur Respir J 1991; 4: 1044–1052.

124 Nickol A, Hart N, Hopkinson NS, et al. Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV. Int J Chron Obstruct Pulmon Dis 2008; 3: 453–462.

125 Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22: 101–111.